A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.

Autor: Polak SB; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands., Van Gool IC; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands., Cohen D; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., von der Thüsen JH; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., van Paassen J; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands. J.van_Paassen@lumc.nl.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2020 Nov; Vol. 33 (11), pp. 2128-2138. Date of Electronic Publication: 2020 Jun 22.

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.

Autor: Temko D; Evolution and Cancer Laboratory, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.; Centre for Maths and Physics in the Life Sciences and Experimental Biology (CoMPLEX), University College London, London, UK.; Department of Computer Science, University College London, London, UK., Van Gool IC; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Rayner E; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Glaire M; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Makino S; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Brown M; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Chegwidden L; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Palles C; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Depreeuw J; KU Leuven (University of Leuven), University Hospitals Leuven, Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Leuven, Belgium.; KU Leuven, Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.; VIB Centre for Cancer Biology, Laboratory for Translational Genetics, Leuven, Belgium., Beggs A; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Stathopoulou C; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Mason J; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Baker AM; Evolution and Cancer Laboratory, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Williams M; Evolution and Cancer Laboratory, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.; Department of Cell and Developmental Biology, University College London, London, UK., Cerundolo V; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Rei M; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK., Taylor JC; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Schuh A; Department of Oncology, University of Oxford, Oxford, UK., Ahmed A; Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Oxford, UK., Amant F; Centre for Gynaecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lambrechts D; KU Leuven, Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.; VIB Centre for Cancer Biology, Laboratory for Translational Genetics, Leuven, Belgium., Smit VT; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Bosse T; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Graham TA; Evolution and Cancer Laboratory, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Church DN; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Tomlinson I; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Publikováno v: The Journal of pathology [J Pathol] 2018 Jul; Vol. 245 (3), pp. 283-296. Date of Electronic Publication: 2018 Apr 30.

Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.

Autor: Van Gool IC; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Ubachs JEH; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Stelloo E; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., de Kroon CD; Department of Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands., Goeman JJ; Department of Medical Statistics and Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands., Smit VTHBM; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Creutzberg CL; Department of Clinical and Radiation Oncology, Leiden University Medical Centre, Leiden, The Netherlands., Bosse T; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands.

Publikováno v: Histopathology [Histopathology] 2018 Jan; Vol. 72 (2), pp. 248-258. Date of Electronic Publication: 2017 Oct 10.

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

Autor: Eggink FA; Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen , Groningen, the Netherlands., Van Gool IC; Department of Pathology, Leiden University Medical Center , Leiden, the Netherlands., Leary A; Department of Medical Oncology, INSERM U981, Gustave Roussy Cancer Center , Villejuif, France., Pollock PM; Queensland University of Technology (QUT), Translational Research Institute , Brisbane, QLD, Australia., Crosbie EJ; Institute of Cancer Sciences, University of Manchester, St Marys Hospital , Manchester, UK., Mileshkin L; Division of Cancer Medicine, Peter MacCallum Cancer Centre , East Melbourne, VIC, Australia., Jordanova ES; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands; Center for Gynecological Oncology Amsterdam, VU Medical Center, Amsterdam, the Netherlands., Adam J; Department of Medical Oncology, INSERM U981, Gustave Roussy Cancer Center , Villejuif, France., Freeman-Mills L; Tumour Genomics and Immunology Group, Oxford Centre for Cancer Gene Research, The Wellcome Trust Centre for Human Genetics, University of Oxford , Oxford, UK., Church DN; Tumour Genomics and Immunology Group, Oxford Centre for Cancer Gene Research, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; Oxford Cancer Centre, Churchill Hospital, Oxford, UK., Creutzberg CL; Department of Clinical Oncology, Leiden University Medical Center , Leiden, the Netherlands., De Bruyn M; Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen , Groningen, the Netherlands., Nijman HW; Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen , Groningen, the Netherlands., Bosse T; Department of Pathology, Leiden University Medical Center , Leiden, the Netherlands.

Publikováno v: Oncoimmunology [Oncoimmunology] 2016 Dec 09; Vol. 6 (2), pp. e1264565. Date of Electronic Publication: 2016 Dec 09 (Print Publication: 2017).

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Autor: Van Gool IC; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Stelloo E; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Nout RA; Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands., Nijman HW; Department of Gynecology, University Medical Center Groningen, Groningen, The Netherlands., Edmondson RJ; Institute of Cancer Sciences, University of Manchester, St Marys Hospital, Manchester, UK., Church DN; Molecular and Population Genetics Laboratory, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.; Oxford Cancer Centre, Churchill Hospital, Oxford, UK., MacKay HJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada., Leary A; Department of Medicine, Gynecology Unit, Gustave Roussy, Villejuif, France., Powell ME; Department of Clinical Oncology, Barts Health NHS Trust, London, UK., Mileshkin L; Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia., Creutzberg CL; Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands., Smit VT; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Bosse T; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2016 Feb; Vol. 29 (2), pp. 174-81. Date of Electronic Publication: 2016 Jan 08.